VRDN.NASDAQViridian Therapeutics, Inc\de

SCHEDULE 13G/A: Venrock Healthcare Capital Partners Reduces Stake in Viridian Therapeutics Below 5%

Sentiment:

Beneficial Ownership Update

📋All filings for Viridian Therapeutics, Inc\de
🔒Login to Follow

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a reduction in their beneficial ownership of Viridian Therapeutics, Inc. common stock to 4.5% as of December 31, 2024.

Worse than expectedThe filing indicates a reduction in the beneficial ownership stake of the Venrock Healthcare Capital Partners group to 4.5%, which is below the 5% threshold typically associated with significant passive investor disclosures. This suggests a decrease in their overall investment or a partial divestment, which can be perceived negatively by the market.

Summary

  • The filing is an Amendment No. 5 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
  • The reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, are acting as a group.
  • As of December 31, 2024, the group beneficially owns an aggregate of 3,575,309 shares of Viridian Therapeutics, Inc. Common Stock.
  • This aggregate ownership represents 4.5% of the Issuer's Common Stock class.
  • The percentage is calculated based on 79,212,747 shares outstanding as of November 7, 2024, plus 1,044,922 shares issuable upon conversion of Series A and Series B preferred stock held by the reporting persons.
  • The reporting persons hold shared voting and dispositive power over all 3,575,309 beneficially owned shares.
  • The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant investor's stake below the 5% threshold, which could imply a reduced level of confidence or a strategic portfolio adjustment by the investor group.

Negatives

  • The reduction in beneficial ownership by a significant institutional investor group (Venrock Healthcare Capital Partners) to below the 5% threshold could be interpreted as a decrease in conviction or a partial exit from their investment in Viridian Therapeutics, Inc.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant institutional investor's position within the biotechnology or pharmaceutical sector, specifically regarding Viridian Therapeutics, Inc. Such changes can sometimes signal shifts in investor confidence or portfolio rebalancing within the healthcare investment landscape.

Stakeholder Impact

  • Shareholders: May view the reduction in a major institutional investor's stake as a negative signal, potentially impacting investor confidence and the company's stock price.

Key Dates

DateDescription
2021-10-14Date of original Schedule 13G filing for Power of Attorney exhibits.
2024-11-07Date of outstanding common stock count (79,212,747 shares) as reported in the Issuer's Form 10-Q.
2024-12-31Date of event which requires filing of this statement (beneficial ownership snapshot date).
2025-02-14Execution and filing date of the Joint Filing Agreement and the Schedule 13G/A.

Recommendation

hold

Keywords

Viridian Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, beneficial ownership, common stock, institutional investment, equity stake, SEC filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.